Available online at www.ujpronline.com
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal
ISSN: 2831-5235 (Print); 2456-8058 (Electronic)

REVIEW ARTICLE

EXPLORING VARIABILITY IN COMPLEX SYSTEMS: A SYNTHESIS OF MICROBIOLOGICAL ENVIRONMENTAL MONITORING, EPIDEMIOLOGICAL TRENDING, AND QUANTITATIVE BIOLOGICAL THEORIES

Mostafa Essam Eissa
Independent Researcher and Consultant, Cairo, Egypt.

Article Info:

Article History:
Received: 11 October 2025
Reviewed: 17 November 2025
Accepted: 24 December 2025
Published: 15 January 2026

Cite this article:
Eissa ME. Exploring variability in complex systems: A synthesis of microbiological environmental monitoring, epidemiological trending, and quantitative biological theories. Universal Journal of Pharmaceutical Research 2025; 10(6): 75-81.
http://doi.org/10.22270/ujpr.v10i6.1464

***Address for Correspondence:**
Dr. Mostafa Essam Eissa, Independent Researcher and Consultant, Cairo, Egypt.
Tel: +20-1006154853
E-mail: *mostafaessameissa@yahoo.com*

Abstract

The advancement of pharmaceutical sciences and public health is fundamentally constrained by our capacity to distinguish meaningful signals from inherent noise within complex, non-linear biological systems. Variability is an omnipresent characteristic of biological data, manifesting as fluctuating bioburden in pharmaceutical water systems, unpredictable waves of infectious disease outbreaks, and stochastic molecular interactions. This exploratory theoretical review synthesizes transdisciplinary research to bridge the conceptual gaps between industrial quality control, global epidemiology, and advanced theoretical frameworks. Moreover, we critically evaluate the application of Statistical Process Control (SPC) and Quantitative Risk Assessment (QRA) as robust methodologies for managing variability across vastly different scales. From the micro-scale challenges of validating disinfection efficacy against resistant microbial spores to the macro-scale patterns of COVID-19 morbidity and the emerging insights from quantitative biology, this manuscript posits that a unified analytical framework is not only beneficial but necessary. Thus, it is argued that chaotic variability in life sciences is not merely random error but often follows decipherable statistical patterns and emergent laws. A deeper understanding of these patterns enables superior predictive modeling, enhanced process control, and more resilient public health interventions. At the end, this synthesis aims to provide for a more integrated, data-driven approach to quality and health in the 21st century.

Keywords: Biological variability, pharmaceutical microbiology, public health epidemiology, quantitative risk assessment, systems biology, statistical process control.

INTRODUCTION

In the rigorous domains of pharmaceutical and medical sciences, variability is frequently perceived as the adversary of quality and predictability. In drug manufacturing, uncontrolled variability can lead to critical batch failures and product recalls; in clinical pharmacology, it underlies the spectrum of inter-individual therapeutic outcomes and adverse drug reactions; and in public health, it manifests as the seemingly uncontrollable ebb and flow of epidemic waves[1-5]. Nevertheless, a paradigm shift is underway, driven by advancements in data science and systems biology[6]. This new perspective suggests that variability is not merely noise to be suppressed but a rich source of information about the underlying state of a system[7]. The "One Health" perspective, which integrally links human, animal, and environmental health, demands a similarly integrated and sophisticated analytical approach[8,9]. Consequently, the historically siloed methodologies where microbiologists conduct colony counts, engineers plot control charts, and physicists model quantum phenomena must converge to address these complex challenges[10].

This review synthesizes a broad spectrum of literature to demonstrate that the principles of Statistical Process Control (SPC), originally engineered for industrial manufacturing, possess the robustness to decipher and manage biological variability[11,12]. Furthermore, we explore how emerging theories in Systems and Quantitative Biology, coupled with Artificial Intelligence (AI), are providing novel, mechanistic explanations for the stochasticity often observed in these systems[13,14]. By mapping the conceptual trajectory from microbiological environmental monitor-ring to global disease trending and toward foundational

biological principles, we establish a continuum of "System Reliability" that is critically relevant to pharmacists, epidemiologists, and biomedical researchers alike. The central thesis of this work is that a transdisciplinary understanding of variability is the key to unlocking next-generation solutions in process validation, therapeutic intervention, and pandemic preparedness following the general concept of preparing narrative review article[15]. Boolean Search String that aided in initial database creation was: ("biological variability" or "inherent variability") and ("Statistical Process Control" or SPC) and ("pharmaceutical microbiology" or "environmental monitoring") and ("public health epidemiology" or "epidemiological trending") and (synthesis or review or framework).

THE micro-scale: Managing variability in pharmaceutical microbiology

The pharmaceutical manufacturing environment represents a paradigm of a controlled, yet inherently chaotic, biological system[16]. Despite rigorous engineering controls, including High Efficiency Particulate Air (HEPA) filtration and sterilization-in-place (SIP) systems, microbial life persists, introducing variability that directly threatens product sterility and patient safety[17]. Literature increasingly underscores the necessity of moving beyond static, compliance-driven "snapshot" monitoring toward dynamic, trend-based analysis that captures the system's temporal behavior[18,19].

Water systems: The hemodynamics of the facility

Pharmaceutical water purification systems constitute a dynamic ecosystem where oligotrophic bacteria, such as members of the *Burkholderia cepacia* complex, can proliferate and form biofilms[20,21]. Researchers have contributed to this understanding, demonstrating that variability in purified water quality is not entirely random but can exhibit discernable patterns linked to the feed source[22]. Independent research utilizing dendrogram analysis and Principal Component Analysis (PCA) has further validated the ability to trace the lineage of microbial contaminants from municipal grids to critical points-of-use within a facility[23]. This finding profoundly implies that the "variability" observed within a controlled cleanroom is often a delayed reflection of the external environmental "variability".

Moreover, the statistical modeling of this bioburden is critical for proactive intervention. Traditional linear trending often fails to capture the seasonality and autoregressive nature of water contamination[24]. Thus, the application of advanced time-series models, such as ARIMA (Auto Regressive Integrated Moving Average), provides a more sophisticated framework for forecasting potential bioburden excursions[25]. By reconceptualizing water quality as a time-series problem rather than a set of isolated compliance tests, manufacturers can transition from a reactive to a predictive stance, anticipating system "noise" and intervening proactively[26].

The disinfection variable: Resistance and recovery

A major source of variability in sterility assurance is the initial level of microbial contamination, known as bioburden[27]. Thus, the interaction between biocides, manufacturing surfaces, and microbial physiology is highly non-linear and context-dependent[28]. A critical concept is the "Neutralization Gap" a term describing the observed variance between the theoretical efficacy of a disinfectant in suspension tests and its practical recovery from surface validation studies[29-32]. Research on peroxygen and silver-based disinfectants has revealed significant discrepancies in the recovery of *Staphylococcus aureus* and *Candida albicans* due to inadequate neutralization of residual biocide[33].

Furthermore, the intrinsic variability in spore resistance is a pivotal factor[34]. Comparative studies between bacterial endospores (e.g., *Bacillus subtilis*) and fungal spores (e.g., *Aspergillus brasiliensis*) exposed to oxidizing agents demonstrate that resistance mechanisms differ fundamentally, necessitating distinct and tailored validation protocols[35]. Additionally, and of critical importance, the presence of interfering substances, such as synthetic detergents, introduces another layer of chemical variability[36]. Eissa *et al*. found that detergent residues could alter the surface disinfection power, potentially by modifying microscopic surface penetrability along with the biocidal synergism with the antimicrobial substances, thereby impacting the sporicidal kinetics of subsequent disinfection steps[34-36]. Therefore, a holistic "cleaning validation" approach that accounts for this chemical interplay is required to minimize variability and ensure consistent microbial lethality.

Environmental monitoring: Signal detection in cleanrooms

The ultimate goal of an Environmental Monitoring (EM) program is to detect the genuine signal of a significant contamination event amidst the background noise of normal facility operations[37-39]. The strategic transition from active (volumetric) to passive (settling plates) air sampling generates datasets with distinct statistical properties[40]. Nevertheless, a comprehensive risk assessment strategy that utilizes both methods synergistically provides a more composite and actionable picture of the "bio-load" settling on critical surfaces[40,41].

Crucially, the evaluation of surface cleanliness using Six Sigma tools allows for the calculation of "Defects Per Million Opportunities" (DPMO) in the context of microbial contamination[42]. This powerful approach transforms qualitative microbiological data into quantitative, engineering-grade metrics, enabling the precise calculation of process capability (C_{pk}) and the statistically robust identification of outlier events that deviate from the established baseline variability[16,42,43]. This data-driven methodology allows resource allocation to be focused on the most critical control points.

The macro-scale: Epidemiological variability and public health

If a pharmaceutical facility represents a micro-system of controlled variability, the global human population constitutes a macro-system of uncontrolled variability that is much harder to control. However, a compelling body of literature demonstrates that the same fundamental statistical principles governing cleanrooms can be applied to understand and manage pandemics,

albeit on a vastly different scale and with greater complexity[44,45].

COVID-19: A case study in global process instability

The COVID-19 pandemic represented a profound, global-scale excursion in public health stability[46]. Several researchers have demonstrated the utility of industrial SPC tools to model this instability[47,48]. By treating daily morbidity and mortality rates as "process outputs", researchers have effectively utilized Attribute Control Charts (specifically u-charts and p-charts) to map the trajectory of the virus across different nations[45,49-53]. Significantly, these analyses revealed that pandemic waves behave analogously to "out-of-control" manufacturing processes[45,49,50]. The consistent breach of "Upper Control Limits" (UCL) often signaled the emergence of new variants or the failure of non-pharmaceutical containment measures[51-54].

Furthermore, the application of the Pareto Principle (the 80/20 rule) to global mortality rates highlighted that the variability in death tolls was not uniformly distributed but heavily skewed towards specific geo-graphical and demographic clusters[55,56]. This finding strongly supports a targeted, precision public health strategy, focusing resources on the "vital few" regions and populations driving a disproportionate share of infections and severe outcomes.

Long-term trending of pathogens

Beyond the acute crisis of COVID-19, data analysis examines the long-term variability of endemic pathogens. Analyses of large-scale surveillance systems, such as the National Outbreak Reporting System (NORS) in the USA, for protozoan parasites like Cryptosporidium and Giardia, have revealed consistent seasonal periodicities and long-term secular trends that are often obscured by short-term stochastic noise[57,58]. By applying quantitative risk analysis and time-series decomposition to these rich datasets, researchers can smooth out random variations and identify underlying ecological and sociological drivers, such as climate patterns, water usage, and agricultural practices[59].

Similarly, the application of SPC to chronic disease metrics, such as cancer mortality rates, provides a "control chart" for national health system performance[60,61]. These studies collectively suggest that public health surveillance must evolve from reactive case counting to predictive, intelligence-driven monitoring, using statistically derived limits to objectively define "endemic stability" versus "abnormal outbreak".

The allied sciences: Engineering control and data forensics

The effective management of variability necessitates robust, transdisciplinary tools. The reviewed bibliography logically extends beyond biology into the realms of engineering and data science, treating "systems control" as a unified discipline applicable to both physical and biological processes[62-65].

Statistical Process Control (SPC) methodologies

The choice of an appropriate statistical tool is paramount for signal clarity. Standard Shewhart control charts rely on the assumption of specific distribution and independent data, an assumption that biological data rarely satisfies. Hence, for monitoring attributes data where the sample size is large and subject to over dispersion, the use of Laney U' charts, which incorporate adjustments for between-sample variation, is strongly advocated[2,66]. This methodology is particularly relevant for monitoring non-filterable liquid products and oral solid dosage forms, where the variance in unit-to-unit bioburden often exceeds the mean[67].

Moreover, the integration of Six Sigma capability analysis into healthcare logistics, such as inventory management and supplier qualification, allows facilities to quantify and manage the variability of their supply chains[68,69]. Thus, the "quality" of a pharmaceutical product is defined not solely by the drug's purity, but also by the reliability and robustness of the entire logistical chain supporting its delivery to the patient[70,71].

Forensic data analysis

In an era of big data and complex supply chains, the ability to detect fraudulent or anomalous variability is critical for patient safety[72,73]. The use of SPC for detecting trends indicative of adulterated or counterfeit pharmaceutical products represents a powerful forensic application of these industrial tools[72]. Additionally, the principles of variability analysis, such as the Pareto principle, find application in diverse fields including computational linguistics and cybersecurity, demons-trating their universal utility in identifying significant signals within noisy datasets[74,75].

The frontier scale: Quantitative biology and theoretical synthesis

The most profound sources of variability may lie at the most fundamental levels of biological organization. The trajectory of modern research suggests that the "noise" observed in cellular and molecular systems can be understood through the lens of quantitative and systems biology[76,77].

Quantitative biology and cellular decision-making

Emerging theories grounded in systems biology propose that cellular processes are inherently stochastic[78]. This stochasticity is not merely experi-mental error but a fundamental feature driving phenotypic variability in isogenic cell populations, a phenomenon known as non-genetic heterogeneity[79,80]. In this context, the "variability" in cellular signaling and gene expression can be a mechanism for probabilistic bet-hedging, allowing microbial popu-lations to survive sudden environmental stresses[81-83].

Understanding these principles is becoming increasingly important for pharmaceutical science, as it impacts drug-receptor dynamics, the emergence of antibiotic persistence, and the efficacy of cancer therapeutics[84,85].

The engineering of biological systems

The convergence of biology and engineering is further exemplified by advances in synthetic biology and biohybrid systems[62,86]. Here, biological variability is not just managed but actively engineered into functional machines, such as living sensors or drug-delivery vectors[87-89]. Furthermore, the challenges of controlling complex systems are universal. The

engineering principles used to manage the physical instability of a spacecraft (e.g., propellantless propulsion concepts) serve as a macro-scale analogy for the biological challenge of maintaining physiological stability in extreme environments, such as during long-duration space missions[90,91].

Finally, the exploration of complex biological systems like the human gut resistome and the application of AI in antibiotic discovery brings the discussion full circle[92,93]. The gut microbiome is accurately described as a dynamic "reservoir" of genetic variability, which advanced machine learning models can mine to predict emerging antimicrobial resistance threats[94]. Thus, the ultimate toolkit for deciphering biological variability appears to be the synergistic combination of deep biological insight and immense computational power.

CONCLUSIONS

The unification of concepts from microbiological monitoring, epidemiological trending, and quantitative biology reveals a powerful narrative: Variability is the fundamental language of complex biological systems, and its interpretation is key to progress. At the Micro-Scale: Variability in pharmaceutical water systems and surface contamination is a quantifiable predictor of system failure, manageable through advanced SPC charts (e.g., Laney U') and Six Sigma methodologies. At the Macro-Scale: Variability in global disease rates follows recognizable statistical approaches (e.g., Pareto) and process control laws, enabling a more systematic, "industrialized" approach to public health surveillance and resource allocation. At the Frontier: Variability in cellular and molecular systems is being recast from noise to a functional component of biological regulation, driven by stochastic principles and amenable to analysis through systems biology and AI. Therefore, this transdisciplinary review concludes that the future of pharmaceutical and public health research lies in the widespread adoption of a "Unified Variability Framework". By applying the rigorous, principled tools of systems engineering and data science to the dynamic data generated by biology, we can progressively decipher the noise, predict the signals of failure, and ultimately safeguard human health with unprecedented precision and foresight.

ACKNOWLEDGEMENTS

None to declare.

AUTHOR'S CONTRIBUTION

Eissa ME: designed the study, performed the statistical re-analysis, manuscript writing, microbiological interpretation, critically reviewed.

DATA AVAILABILITY

Data will be made available on request.

CONFLICT OF INTEREST

No conflict of interest is associated with this work.

REFERENCES

1. Eissa ME. Variable and attribute control charts in trend analysis of active pharmaceutical components: Process efficiency monitoring and comparative study. Experim Med 2018;1(1):32-44. *https://doi.org/10.31058/j.em.2018.11003*
2. Eissa ME. Application of Laney control chart in assessment of microbiological quality of oral pharmaceutical filterable products. Bangladesh J Scient Indust Res 2017 Oct 3;52(3):239-46. *https://doi.org/10.3329/bjsir.v52i3.34160*
3. Eissa ME. Current perspective in quality control examining and extended researching for certain aspects of active pharmaceutical ingredient using statistical process control. Acta Natura et Scientia 2024 May 24;5(1):31-40. *https://doi.org/10.61326/actanatsci.v5i1.4*
4. Eissa ME. Statistical process control research of toxicological outbreaks in USA: an opinion from long-term web-based trending for selected cases. MOJ Toxicol. 2019;5(2):73-6. *https://doi.org/10.15406/mojt.2019.05.00157*
5. Eissa M. Descriptive analysis of coronavirus disease cases based on geographical distribution in Canadian provinces/territories: Statistical investigation into epidemiological pattern. Academia Lett 2022 Jan 1. *https://doi.org/10.20935/AL5191*
6. Potthast T. Paradigm shifts versus fashion shifts? Systems and synthetic biology as new epistemic entities in understanding and making 'life'. EMBO Reports 2009 Aug 1;10(S1):S42-5. *https://doi.org/10.1038/embor.2009.130*
7. Huang J, Xu Y, Wang Q, *et al*. Foundation models and intelligent decision-making: Progress, challenges, and perspectives. The Innovation 2025 May 12. *https://doi.org/10.1016/j.xinn.2025.100948*
8. Eissa M. Investigating the gut microbiome's role in antibiotic resistance in companion animals. J Res Vet Sci 2024 May 20; 2(4):159-174. *https://doi.org/10.5455/JRVS.20240429060752*
9. Eissa M. Climate change and its impact on animal health: adapting and mitigating the risks. Eu J Sci Res Rev 2024 May 16;1(1): 20-42. *https://doi.org/10.5455/EJSRR.20240417024244*
10. National academies of sciences, engineering, and medicine. Division on earth and life studies, division on engineering and physical sciences, board on life sciences, board on physics and astronomy, & committee on biological physics/physics of living systems: A Decadal Survey 2022. What Physics Problems Do Organisms Need to Solve. Physics of Life.
11. Eissa ME. Study of parameters affecting infection risk from contaminated injectable products using multiple spot contamination model: A case study of insulin vials. Journal of Chinese Pharmaceutical Sciences. 2016 Nov 26;11. *https://doi.org/10.5246/jcps.2016.11.093*
12. Eissa ME. Application of control charts in monitoring of surgical site infection trending records using statistical software. Asian J App Sci 2019;12(2):76-84. *https://doi.org/10.3923/ajaps.2019.76.84*
13. Eissa ME. Quantum biology from theory to the future of medicine and pharmacy: A review on a revolutionary change in our perception of life. Universal J Pharm Res 2024 Nov 15. *https://doi.org/10.22270/ujpr.v9i5.1199*

14. Eissa M. AI-based discovery of a new class of antibiotics: implications, challenges, and opportunities for combating antibiotic resistance. J Med Res Rev 2024 Jul 12;2(3):91-104. *https://doi.org/10.5455/JMRR.20240430060232*
15. Eissa M. Mastering the art of efficient literature reviews: A practical guide for medical professionals and students. 2025;4(2): 245-258. *https://doi.org/10.63475/yjm.v4i2.0141*
16. Eissa ME, Mahmoud AM, Nouby AS. Statistical process control in the evaluation of microbiological surface cleanliness quality and spotting the defects in clean area of pharmaceutical manufacturing facility. Haya: The Saudi J Life Sci 2016; 1 (1): 1. 2016;17. *https://doi.org/10.36348/sjls*
17. Eissa M. Studies of microbial resistance against some disinfectants: Microbial distribution and biocidal resistance in pharmaceutical manufacturing facility. LAP Lambert Academic Publishing; 2014.
18. Eissa ME. Conventional culture media: An outdated microbiological tool but still useful. Int J Drug Disc 2018;2:11.
19. Eissa M. Use of RMMs in quality control: Challenges and benefits. Eur Pharm Rev 2015 Oct 22;20(5):8-10.
20. Eissa M. Diversity of bacteria in pharmaceutical water: Significance and impact on quality. European Pharmaceutical Review 2015;53.
21. Eissa M. A novel approach in assessing the antimicrobial efficacy of eye drop products. Eur Pharm Rev 2016 Apr; 21(2):40-43.
22. Eissa ME, Rashed ER, Eissa DE. Dendrogram analysis and statistical examination for total microbiological mesophilic aerobic count of municipal water distribution network system. High Tech Innov J 2022 Mar;3(1):28-36. *https://doi.org/10.28991/HIJ-2022-03-01-03*
23. Eissa M, Rashed E, Eissa D. Principal component analysis in long term assessment of total viable plate count of municipal water distribution network system in healthcare facility. Environmental Res Tech 2022;5(2):165-71. *https://doi.org/10.35208/ert.1062683*
24. Box GE, Jenkins GM, Reinsel GC, Ljung GM. Time series analysis: Forecasting and control. John Wiley & Sons; 2015 May 29.
25. Eissa ME. Modeling microbiological counts in purified water at a healthcare facility using ARIMA. Quantum J Med Health Sci 2025 Jun 28;4(3):56-68. *https://doi.org/10.55197/qjmhs.v4i3.158*
26. Hyndman RJ, Athanasopoulos G. Forecasting: Principles and practice. OTexts; 2018 May 8.
27. Rutala WA, Weber DJ. Guideline for disinfection and sterilization in healthcare facilities 2008.
28. Eissa ME. Biocidal verification program for healthcare facilities: evaluation of the efficacy and microbial tolerance of disinfectants. J Pub Health Comm Med 2024 Mar 6;1(2):60-69. *https://doi.org/10.5455/JPHCM.20240123080736*
29. Eissa ME, Eissa ME. Limitations of the current chemical neutralization tests for assessment of microbial recovery from antimicrobials: A new prospective approach. Int J Micro Allied Sci 2016;2(4):1-5.
30. Eissa ME, Mahmoud AM. Assessment of modified preservation formulae after optimizing preliminary neutralization evaluation study. Int J Multidis Res Stud Develop 2015;1(2):5-11.
31. Eissa ME, Ashour MS, Mansy MS. Neutralizer evaluation study of some microbial isolates against two strong disinfectants with and without the presence of synthetic detergent. World Appl Sci J 2012 Jan 1;20:823-31. *https://doi.org/10.5829/idosi.wasj.2012.20.06.71172*
32. Eissa M. Validation of microbial recovery of pharmaceutically important gram-negative bacteria from peroxygen/silver based disinfectants and evaluation of their degree of corrosiveness. Food Pharma Int 2017 Jan 1;1(2):41-58. *https://doi.org/10.5530/fpi.1.2.1*
33. Eissa ME, Nouby AS. Recovery of gram-positive cocci and *Candida albicans* from peroxygen/silver-based disinfectants. Polish J Microbiol 2016;65(1):3. *https://doi.org/10.5604/17331331.1197271*
34. Eissa ME, Nouby AS. Validation of spore-forming organism's recovery from peroxygen-based disinfectants. J Pharm Res Clin Pract 2014;4(2):23-32.
35. Eissa ME, Abd El Naby M, Beshir MM. Bacterial vs. fungal spore resistance to peroxygen biocide on inanimate surfaces. Bulletin Faculty Pharmacy, Cairo University 2014 Dec 1;52(2):219-24. *https://doi.org/10.1016/j.bfopcu.2014.06.003*
36. Eissa ME, Ashour MS, Mansy MS. Impact of synthetic detergent on sporicidal activity in pharmaceutical facility. Egyptian Academic J Biol Sci G. Microbiol 2013 Jun 1;5(1):43-50. *https://doi.org/10.21608/eajbsg.2013.16644*
37. Brunckhorst KF, Abri M, Bibby S, *et al*. Environmental monitoring plan. Lawrence Livermore National Lab.(LLNL), Livermore, CA (United States); 2019 Oct 29. *https://doi.org/10.2172/1579626*
38. Eissa ME. A non-parametric framework for analyzing spatial heterogeneity and contamination pathways in healthcare environments. Universal J Pharm Res 2025; 10(4): 26-31. *https://doi.org/10.22270/ujpr.v10i4.1390*
39. Eissa ME. A systems based approach to microbiological quality assessment in a healthcare facility's water distribution network: A case study. Universal J Pharm Res 10(4): 96-102. *https://doi.org/10.22270/ujpr.v10i4.1400*
40. Eissa ME, Mahmoud AM, Nouby AS. Active versus passive microbiological air sampling risk assessment: Relation and comparative study in pharmaceutical industry. Research Reviews: A J Pharm Sci 2016;7(1):13-27.
41. Eissa M, Mahmoud A, Nouby A. Evaluation and failure risk of microbiological air quality in production area of pharmaceutical plant. RGUHS J Pharm Sci 2016;5:155-66. *https://doi.org/10.5530/rjps.2015.4.5*
42. Eissa ME, Seif M, Fares M. Assessment of purified water quality in pharmaceutical facility using six sigma tools. Int J Qual Assur 2015;6(2):54-72.
43. Eissa M, Rashed E. Evaluation of microbiological cleanliness of machines/equipment through rinse technique using statistical process control. EMU J Pharm Sci 2023 Jan 7;6(1):1-2. *https://doi.org/10.54994/emujpharmsci.1196909*
44. Eissa ME. COVID-19 impact on public health in Bangladesh: A comprehensive analysis of morbidity, mortality and future scenarios. Acta Natura et Scientia. 2025 Jun 24;6(1):55-65. *https://doi.org/10.61326/actanatsci.v6i1.292*
45. Eissa DE, Rashed ER, Eissa ME. A study of morbidity and mortality from COVID-19 in India. Sci Medicine J 2022 Mar 1;4(1):25-38. *https://doi.org/10.28991/SciMedJ-2022-0401-03*
46. Eissa ME. A holistic perspective on the impact of COVID-19 on the global population in terms of morbidity and mortality rates: Is humanity ready to face future pandemics ? Universal J Pharm Res 2023; 8(6):68-71. *https://doi.org/10.22270/ujpr.v8i6.1044*
47. Eissa ME, Rashed ER. Analysis and modeling of morbidity and mortality from coronavirus outbreak in Brazil: A case study of public health challenge using unique statistical tools. J Health Sci Res 2023;8(2):57-61. *https://doi.org/10.25259/JHSR_3_2023*

48. Essam M. Application of industrial statistical tools in quantitative analysis of COVID-19 pandemic. Asian HHM-Knowledge Bank. 2020.
49. Jewell NP, Lewnard JA, Jewell BL. Caution warranted: Using the institute for health metrics and evaluation model for predicting the course of the COVID-19 pandemic. Annals Internal Med 2020 Aug 4;173(3):226-7. *https://doi.org/10.7326/M20-1565*
50. Eissa ME. Studies on morbidities and mortalities from COVID-19: Novel public health practice during pandemic periods. Asian J Appl Sci 2023;16(3):84-94. *https://doi.org/10.3923/ajaps.2023.84.94*
51. Rashed ER, Eissa ME. Global assessment of morbidity and mortality pattern of CoVID-19: Descriptive statistics overview. Iberoamerican J Med 2020;2(2):68-72. *https://doi.org/10.5281/zenodo.3744147*
52. Eissa M. Modeling of COVID-19 major outbreak wave through statistical software: quantitative risk evaluation and description analysis. Eskişehir Turkish World App Res Center Pub Health J 2022;7(1):145-61. *https://doi.org/10.35232/estudamhsd.1024129*
53. Eissa D, Rashed E, Eissa M. Measuring public health effect of coronavirus disease 2019: A novel perspective in healthcare in pandemic times. Medical J Western Black Sea 2023;7(2):266-8. *https://doi.org/10.29058/mjwbs.1257163*
54. Mostafa Eissa ME. Surveillance of cyclospora cayetanensis epidemics in USA from long-term national outbreaks reporting system-based monitoring: An observational study using statistical process control methodologies. Iberoamerican J Med 2020;2(1):4-9. *https://dx.doi.org/10.5281/zenodo.3549545*
55. Eissa ME, Rashed ER, Eissa DE. Implementation of the Pareto principle in focus group generation based on global coronavirus disease morbidity and mortality rates. Highlights Bio Sci 2022 Aug 24;5. *https://doi.org/10.36462/H.BioSci.202204*
56. Eissa M, Rashed ER. Descriptive epidemiological study of coronavirus disease distribution in specific geographic location: Unique public health practice in outbreak analysis. Turkish J Public Health 2023 Jan 1;21(1):144-51. *https://doi.org/10.20518/tjph.1112614*
57. Eissa ME. Long-term monitoring of giardia as an etiological agent for food-borne outbreaks in USA: A brief report. Open J Nutr Food Sci 2019;1:10-3.
58. Essam Eissa M. Monitoring of *Cryptosporidium* spp. outbreaks using statistical process control tools and quantitative risk analysis based on NORS long-term trending. Microbiol J 2017;9(1):1-7. *https://doi.org/10.3923/mj.2019.1.7*
59. Naumova EN, Jagai JS, Matyas B, DeMaria A, MacNeill IB, Griffiths JK. Seasonality in six enterically transmitted diseases and ambient temperature. Epidemiology Infect 2007 Feb;135(2):281-92. *https://doi.org/10.1017/S0950268806006698*
60. Rashed ER, Eissa ME. Long-term monitoring of Cancer Mortality Rates in USA: A descriptive analysis using statistical process control tools. Iberoamerican J Med 2020;2(2):55-60. *https://dx.doi.org/10.5281/zenodo.3740610*
61. Rashed ER, Eissa ME. Long-Term quantitative assessment of women survivability from cancer: a unique descriptive analysis. Highlights Biosci 2020 Jul 5;3:1-8. *https://doi.org/10.36462/H.BioSci.20208*
62. Eissa ME. Biobots-the future of biomedical engineering: A mini review. Universal J Pharm Res 2025; 10(2): 91-93. *https://doi.org/10.22270/ujpr.v10i2.1319*
63. Eissa ME. Antimatter: The potential impact on the future of medical and pharmaceutical industries. Universal J Pharm Res 2025; 10(2): 70-78. *https://doi.org/10.22270/ujpr.v10i2.1317*
64. Eissa ME. Dawn of synthetic biology engineering life at the microscopic scale: A review. Universal J Pharm Res 2025; 10(1): 61-68. *https://doi.org/10.22270/ujpr.v10i1.1275*
65. Eissa ME. Quantum biology from theory to the future of medicine and pharmacy: A review on a revolutionary change in our perception of life. Universal J Pharm Res 2024; 9(5): 113-121. *https://doi.org/10.22270/ujpr.v9i5.1199*
66. Laney DB. Improved control charts for attributes. Quality Control Appl Stat 2003;48(5):497-8. *https://doi.org/10.1081/QEN-120003555*
67. Eissa M. Statistical process control and capability six-pack for conductivity measurement in medicinal chemical industry. J Pharmacol Pharmaceut Res 2024 Feb 6;1(1):9-14. *https://doi.org/10.5455/JPPR.20240111092356*
68. Eissa M, Rashed E. Application of statistical process optimization tools in inventory management of goods quality: supplier's evaluation in healthcare facility. J Turkish Operat Manag 2020 Jun 6;4(1):388-408.
69. Essam M. Pharmaceutical component kinetics. Pharma Focus Asia. Retrieved on July. 2023;11:2023.
70. Eissa M, Rashed E. Inventory digital management using statistical process control analysis in healthcare industry. J Business The Digital Age 2020;3(2):123-8. *https://doi.org/10.46238/jobda.688641*
71. Eissa M. Implementation of trending charts in analysis of inventory pattern. European Pharm Rev 2021 Apr;26(2):30-3.
72. Eissa ME. Adulterated pharmaceutical product detection using statistical process control. Bangladesh Pharm J 2018 Aug 15;21(1):7-15. *https://doi.org/10.3329/bpj.v21i1.37900*
73. Eissa ME. Assessment of some inspection properties of commonly used medicinal excipients using statistical process control for monitoring of manufacturer quality. Acta Natura et Scientia. 2024 May 24;5(1):19-30. *https://doi.org/10.61326/actanatsci.v5i1.3*
74. Eissa ME. Sentiment analysis of a translated text of the Qur'ān using the pareto principle. Islamic Stud 2023 Sep 30;62(3):379-402. *https://doi.org/10.52541/isiri.v62i3.2706*
75. Chandola V, Banerjee A, Kumar V. Anomaly detection: A survey. ACM computing surveys (CSUR). 2009 Jul 30;41(3):1-58. *https://doi.org/10.1145/1541880.1541882*
76. Vo HD, Forero-Quintero LS, Aguilera LU, Munsky B. Analysis and design of single-cell experiments to harvest fluctuation information while rejecting measurement noise. Frontiers Cell Deve Biol 2023 May 26;11:1133994. *https://doi.org/10.3389/fcell.2023.1133994*
77. Steiner UK, Tuljapurkar S, Roach DA. Quantifying the effect of genetic, environmental and individual demographic stochastic variability for population dynamics in Plantago lanceolata. Sci Rep 2021 Nov 30;11(1):23174. *https://doi.org/10.1038/s41598-021-02468-9*
78. Gorin G, Vastola JJ, Pachter L. Studying stochastic systems biology of the cell with single-cell genomics data. Cell Syst 2023 Oct 18;14(10):822-43. *https://doi.org/10.1016/j.cels.2023.08.004*
79. Raj A, Van Oudenaarden A. Nature, nurture, or chance: Stochastic gene expression and its consequences. Cell 2008 Oct 17;135(2):216-26. *https://doi.org/10.1016/j.cell.2008.09.050*
80. Lewis JS, van Oijen AM, Spenkelink LM. Embracing heterogeneity: Challenging the paradigm of replisomes as deterministic machines. Chem Rev 2023 Nov 16;123(23):13419-40. *https://doi.org/10.1021/acs.chemrev.3c00436*

81. Ackermann M. A functional perspective on phenotypic heterogeneity in microorganisms. Nature Rev Microbiol 2015 Aug;13(8):497-508. *https://doi.org/10.1038/nrmicro3491*
82. Jolly MK, Kulkarni P, Weninger K, Orban J, Levine H. Phenotypic plasticity, bet-hedging, and androgen independence in prostate cancer: Role of non-genetic heterogeneity. Frontiers Oncol 2018 Mar 6;8:50. *https://doi.org/10.3389/fonc.2018.00050*
83. Bashir T, Brackston RD, Waite C, *et al*. Molecular origins of transcriptional heterogeneity in diazotrophic *Klebsiella oxytoca*. Msystems 2022 Oct 26;7(5):e00596-22. *https://doi.org/10.1128/msystems.00596-22*
84. Brock A, Chang H, Huang S. Non-genetic heterogeneity- A mutation-independent driving force for the somatic evolution of tumours. Nature Rev Genet 2009 May;10(5):336-42. *https://doi.org/10.1038/nrg2556*
85. Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumourrelapse:‘ What does not kill me strengthens me’. British J Cancer 2015 May; 112(11):1725-32. *https://doi.org/10.1038/bjc.2015.146*
86. Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nature Rev Drug Discov 2022 Sep;21(9):655-75. *https://doi.org/10.1038/s41573-022-00476-6*
87. Peng H, Chen IA, Qimron U. Engineering phages to fight multidrug-resistant bacteria. Chem Rev 2024 Dec 16;125(2):933-71.
88. Ho D, Quake SR, McCabe ER, *et al*. Enabling technologies for personalized and precision medicine. Trends Biotech 2020 May 1;38(5):497-518. *https://doi.org/10.1016/j.tibtech.2019.12.021*
89. Abdullah KM, Sharma G, Singh AP, Siddiqui JA. Nanomedicine in cancer therapeutics: Current perspectives from bench to bedside. Mol Canc 2025 Jun 9;24(1):169. *https://doi.org/10.1186/s12943-025-02368-w*
90. Eissa ME. Unconventional Space Technologies: Engineering design and physics extension to propellantless propulsion. J Eng Res Rev 2024 Aug 30;1(2):60-67. *https://doi.org/10.5455/JERR.20240801110837*
91. Eissa ME. Beyond the rocket: A mini review of propellantless propulsion technologies and concepts. J Eng Res Rev 2024;1(1):1-14. *https://doi.org/10.5455/JERR.20240604120507*
92. Eissa ME. Resistome of the human gut microbiome–A reservoir for emerging threats: A Mini review. J Exp Lab Med 2024 Aug 10;1(1):32-42. *http://doi.org/10.5455/JELM.20240527084438*
93. Eissa M. AI-based discovery of a new class of antibiotics: implications, challenges, and opportunities for combating antibiotic resistance. J Med Res Rev 2024 Jul 12;2(3):91-104. *http://doi.org/10.5455/JMRR.20240430060232*
94. Stokes JM, Yang K, Swanson K, *et al*. A deep learning approach to antibiotic discovery. Cell 2020 Feb 20; 180(4):688-702. *https://doi.org/10.1016/j.cell.2020.01.021*